Localized fat is a difficult aesthetic problem that affects both women and men, even people with normal weight that follow a balanced diet, work out and do not smoke. Examples of localized fat deposits are saddlebags in women and belly fat in men. In other cases, stubborn fat can be seen on a wider area, such as in arms, thighs, buttocks, back, knees, lower legs, under the chin and generally anywhere on the body.
Spot-targeted lipolysis is a non-invasive therapy aiming at reducing stubborn fat. The treatment involves subcutaneous injections administered into the fatty area just under the skin, exactly where the problem exists.
DESOBODY is an injection lipolysis treatment that breaks down fat from the desired body areas. The active ingredients are administered by a special injection technique that follows a specific protocol, directly into the subcutaneous adipose tissue using fine, flexible needles.
Pain is relatively minimal. After treatment, some erythema (redness) or a slight swelling may occur, which recede completely a few days later.
The astonishing effects of this treatment are caused by DESOBODY’s main active ingredient, deoxycholic acid. Deoxycholic acid is a bile acid that is naturally produced by the body (specifically the liver) and helps in destroying fat cells.
In fact, the treatment causes fat liquidation by damaging fat cells and eventually leading them to die. After fat is broken down, cellular debris is cleared away naturally through the body’s immune system, while the unbound fat cells (adipocytes) are metabolized and converted into energy. The number of sessions required depends on the condition being treated and the reactions of the fatty (adipose) tissue. The number of sessions required is, on average, 3-6 every 20-30 days.
The effects are evident after just two sessions and get progressively better until the final impressive result. DESOBODY can be applied on: • Buttocks • Abdomen • Arms • Lower back • Hips • Saddlebags • Knees • Chest • Inner thighs • Double-chin • Pseudogynecomastia
The treatment is approved by the U.S. Food and Drug Administration (FDA) and the EU (CE).